切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2019, Vol. 09 ›› Issue (03) : 149 -153. doi: 10.3877/cma.j.issn.2095-1221.2019.03.004

所属专题： 专题评论； 文献；

论著

外周血MDSC水平及NLR、PLR比值对结直肠癌患者临床预后评估的价值
李奕建1,†(), 钟世彪2, 陈利生3   
  1. 1. 532200　崇左，广西崇左市人民医院普外科
    2. 530021　南宁，广西民族医院肛肠科
    3. 530021　南宁，广西医科大学第一附属医院结直肠肛门外科
  • 收稿日期:2019-04-29 出版日期:2019-06-01
  • 通信作者: 李奕建
  • 基金资助:
    崇左重点研发计划(崇科FA2018021)

Value of MDSC level and NLR/PLR ratio in peripheral blood of patients with colorectal cancer in guiding clinical prognosis evaluation

Yijian Li1,†(), Shibiao Zhong2, Shengchen Li3   

  1. 1. General Surgery, People's Hospital of Guangxi Chongzuo City, Chongzuo 532200, China
    2. Guangxi National Hospital Anorectal, Nanning 530021, China
    3. Department of Colorectal and Anal Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
  • Received:2019-04-29 Published:2019-06-01
  • Corresponding author: Yijian Li
  • About author:
    Corresponding author: Li Yijian, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李奕建, 钟世彪, 陈利生. 外周血MDSC水平及NLR、PLR比值对结直肠癌患者临床预后评估的价值[J]. 中华细胞与干细胞杂志(电子版), 2019, 09(03): 149-153.

Yijian Li, Shibiao Zhong, Shengchen Li. Value of MDSC level and NLR/PLR ratio in peripheral blood of patients with colorectal cancer in guiding clinical prognosis evaluation[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2019, 09(03): 149-153.

目的

探讨结直肠癌患者外周血髓源抑制细胞（MDSC）水平及中性粒细胞淋巴细胞比值（NLR）、血小板淋巴细胞比值（PLR）对临床预后评估的价值。

方法

选取广西崇左市人民医院普外科2013年5月至2018年5月收治的183例结直肠癌患者及50名健康体检者，分别纳入患者组、对照组。检测患者组治疗前、对照组入组时外周血MDSC水平及NLR、PLR比值，记录患者组治疗前、治疗后1个月上述指标变化，并比较治疗有效、无效患者治疗前上述指标的差异。采用卡方检验、t检验及受试者工作特征曲线（ROC）进行统计学分析。

结果

患者组治疗前MDSC比例及NLR、PLR比值分别为（4.26±0.99）﹪、3.05±0.59、146.45±29.71，均高于对照组的（0.71±0.15）﹪、1.62±0.37、90.92±13.88，差异具有统计学意义（t?= 25.238、16.272、12.824，P均< 0.05）。患者治疗后1个月MDSC比例及NLR、PLR比值均较治疗前下降，差异具有统计学意义（P均< 0.05）。183例患者中，111例肿瘤未进展，纳入治疗有效组，72例肿瘤进展，纳入治疗无效组。治疗有效组治疗前MDSC比例及NLR、PLR比值分别为（4.06±0.61）﹪、2.73±0.40、136.18±26.11，均低于治疗无效组的（4.57±0.42）﹪、3.54±0.31、162.29±18.64，差异具有统计学意义（t?= 6.202、14.572、7.353，P均< 0.05）。ROC曲线示，以治疗前MDSC≥4.22﹪、NLR≥3.21、PLR≥151.60为截断值，MDSC比例联合NLR、PLR比值预测结直肠癌患者治疗无效的曲线下面积为0.909（P < 0.05）。

结论

结直肠癌患者外周血MDSC水平及NLR、PLR比值升高，且较高的MDSC水平及NLR、PLR比值意味着预后不良。

关键词: 结直肠癌, 髓源抑制细胞, 中性粒细胞/淋巴细胞比值, 血小板/淋巴细胞比值, 预后评估
Objective

To explore the value of Myeloid-derived suppressor cell (MDSC) level in peripheral blood, neutrophil to lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) in guiding clinical prognosis evaluation of patients with colorectal cancer.

Methods

183 patients with colorectal cancer and 50 health examinees admitted to our hospital from May 2013 to May 2018 were enrolled in the patient group and the control group respectively. The levels of MDSC and the ratio of NLR to PLR in peripheral blood of patients before and after treatment were measured. The changes of the above indexes in patients before and after treatment were recorded, and the differences of the above indexes in patients with effective and ineffective treatment before treatment were compared. Chi-square test, t-test and receiver operating characteristic (ROC) were used for statistical analysis.

Results

Before treatment, the ratio of MDSC, NLR and PLR in patients group were (4.26±0.99) ﹪, (3.05±0.59) , (146.45±29.71) respectively, which were higher than those in the control group (0.71 ±0.15) ﹪, (1.62 ±0.37) , (90.92 ±13.88) . The difference was statistically significant (t?= 25.238, 16.272, 12.824, P all < 0.05) . The ratio of MDSC, NLR and PLR decreased one month after treatment, and the difference was statistically significant (P < 0.05) . Among 183 patients, 111 cases were included in the effective treatment group and 72 cases were included in the ineffective treatment group. The ratio of MDSC, NLR and PLR in the effective group before treatment were (4.06±0.61) ﹪, (2.73±0.40) , (136.18±26.11) , respectively, which were lower than those in the ineffective group (4.57±0.42) ﹪, (3.54±0.31) , (162.29±18.64) , respectively (t?= 6.202, 14.572, 7.353, P all < 0.05) . ROC curve showed that the area under the curve of MDSC (> = 4.22﹪) , NLR (> = 3.21) , PLR (> = 151.60) before treatment was 0.909 (P < 0.05) .

Conclusion

The level of MDSC and the ratio of NLR to PLR of the peripheral blood in patients with colorectal cancer are significantly increased, and the higher MDSC level and the ratio of NLR to PLR imply poor prognosis.

Key words: Colorectal cancer, Myelogenous suppressor cells, Neutrophil-lymphocyte ratio, Platelet-lymphocyte ratio, Prognostic evaluation
表1 患者组与对照组检测结果比较（±s）
分组 例数 MDSC（﹪） NLR PLR
患者组 183 4.26±0.99 3.05±0.59 146.45±29.71
对照组 50 0.71±0.15 1.62±0.37 90.92±13.88
t值 ? 25.238 16.272 12.824
P值 ? < 0.01 < 0.01 < 0.01
表2 患者治疗前后检测结果比较（±s）
时期 例数 MDSC（﹪） NLR PLR
治疗前 183 4.26±0.99 3.05±0.59 146.45±29.71
治疗后1个月 183 2.28±0.42 2.27±0.39 118.65±25.30
t值 ? 24.907 14.919 9.637
P值 ? < 0.01 < 0.01 < 0.01
表3 治疗有效组与治疗无效组治疗前检测结果比较（±s）
时期 例数 MDSC（﹪） NLR PLR
治疗有效组 111 4.06±0.61 2.73±0.40 136.18±26.11
治疗无效组 72 4.57±0.42 3.54±0.31 162.29±18.64
t值 ? 6.202 14.572 7.353
P值 ? < 0.01 < 0.01 < 0.01
表4 MDSC、NLR、PLR单独及联合评估结直肠癌患者治疗无效的效能分析
指标 截断值 灵敏度（﹪） 特异性（﹪） 曲线下面积
MDSC ≥4.22﹪ 87.90 86.82 0.881
NLR ≥3.21 85.06 87.99 0.878
PLR ≥151.60 81.74 85.06 0.824
MDSC＋NLR＋PLR ? 90.13 88.25 0.909
图1 MDSC比例及NLR、PLR比值预测结直肠癌患者治疗无效的ROC曲线
[1]
Kumar V,Patel S,Tcyganov E, et al. The Nature of Myeloid-Derived suppressor cells in the tumor microenvironment[J]. Trends Immunol, 2016, 37(3):208-220.
[2]
Veglia F,Perego M,Gabrilovich D. Myeloid-derived suppressor cells coming of age[J]. Nat Immunol, 2018, 19(2):108-119.
[3]
张勇超,谢建国,韩广森, 等. 直肠癌患者外周血髓源抑制细胞的检测及其临床意义[J]. 中华胃肠外科杂志, 2017, 20(7):798-802.
[4]
全雄男,朴美华,刘兰. 术前NLR与PLR对结直肠癌预后的意义[J]. 中国肿瘤外科杂志, 2016, 8(6):369-372.
[5]
Chun E,Lavoie S,Michaud M, et al. CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function[J]. Cell Rep, 2015, 12(2):244-257.
[6]
Inamoto S,Itatani Y,Yamamoto T, et al. Loss of SMAD4 promotes colorectal cancer progression by accumulation of Myeloid-Derived suppressor cells through the CCL15-CCR1 chemokine axis[J]. Clin Cancer Res, 2016, 22(2):492-501.
[7]
Pinton L,Solito S,Damuzzo V, et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression[J]. Oncotarget, 2016, 7(2):1168-1184.
[8]
王永仿,许联红,恽志华, 等. 结直肠癌患者外周血G-MDSC和M-MDSC水平与疗效的相关性分析[J]. 细胞与分子免疫学杂志, 2018, 34(6):70-75.
[9]
Ouyang LY,Wu XJ,Ye SB, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer[J]. J Transl Med, 2015, 13(1):47.
[10]
Umansky V,Blattner C,Gebhardt C, et al. The role of Myeloid-Derived suppressor cells (MDSC) in cancer progression[J]. Vaccines, 2016, 4(4):36.
[11]
张勇超,李潜,谢建国, 等. 直肠癌及癌前病变患者外周血髓源抑制细胞的表达及其临床意义[J]. 癌症进展, 2018, 16(4):503-505.
[12]
Hossain F,Al-Khami AA,Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies[J]. Cancer Immunol Res, 2015, 3(11):1236-1247.
[13]
邱琛. 奥沙利铂对结直肠癌肿瘤微环境中MDSCs分化调控的影响及机制初探[D]. 广州: 南方医科大学, 2017 .
[14]
王国振. 髓源抑制性细胞对结直肠癌发生发展的影响及机制初探[D]. 广州: 南方医科大学, 2015 .
[15]
Kilincalp S,Coban S,Akinci H, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma[J]. Eur J Cancer Prev, 2015, 24(4):328-333.
[16]
Zou ZY,Liu HL,Ning N, et al. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer[J]. Oncol Lett, 2016, 11(3):2241-2248.
[17]
陈小林,姚国强,刘剑荣. 术前外周血中NLR、d-NLR、PLR和LMR四种比值在结直肠癌患者预后诊断中的价值[J]. 中国免疫学杂志, 2015, 31(10):1389-1393.
[18]
Koh CH,Bhoo-Pathy N,Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer[J]. Br J Cancer, 2015, 113(1):150-158.
[1] 王友芳, 李兴超, 朱晓松, 刘清敏, 张建国, 杨淑红, 相然, 张蒙蒙, 车峰远. 预后营养指数对急性颅内动脉粥样硬化性大血管闭塞患者预后评估价值分析[J]. 中华危重症医学杂志(电子版), 2023, 16(03): 193-197.
[2] 彭国兵, 费建平. 影响患者永久性结肠造口的状况及因素[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(03): 264-268.
[3] 陈润芝, 杨东梅, 徐慧婷. 信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌：个案报道并文献复习[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 431-435.
[4] 鄂一民, 孙司正, 范小彧, 喻春钊. 结直肠癌粪便筛查的现状与展望[J]. 中华结直肠疾病电子杂志, 2023, 12(04): 331-336.
[5] 王小娜, 谭微, 李悦, 姜文艳. 预测性护理对结直肠癌根治术患者围手术期生活质量、情绪及并发症的影响[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 525-529.
[6] 梁文龙, 曹杰, 黄庆, 林泳, 黄红丽, 杨平, 李冠炜, 胡鹤. 信迪利单抗联合瑞戈非尼治疗晚期结直肠癌的疗效与安全性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 409-413.
[7] 刘代江, 蒋俊艳, 万晓强, 马莎英. 结直肠癌肝转移患者生存状况及预后影响因素分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 284-288.
[8] 王健, 赵海剑, 孙静, 张晓雨, 陈柏羽. LncRNA SNHG4表达与结直肠癌预后的关系[J]. 中华消化病与影像杂志(电子版), 2023, 13(03): 139-144.
[9] 李永胜, 孙家和, 郭书伟, 卢义康, 刘洪洲. 高龄结直肠癌患者根治术后短期并发症及其影响因素[J]. 中华临床医师杂志(电子版), 2023, 17(9): 962-967.
[10] 王飞飞, 王光林, 孟泽松, 李保坤, 曹龙飞, 张娟, 周超熙, 丁源一, 王贵英. 敲低IMPDH1对结肠癌SW480、HT29细胞生物功能的影响[J]. 中华临床医师杂志(电子版), 2023, 17(08): 884-890.
[11] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
[12] 王亚丹, 吴静, 黄博洋, 王苗苗, 郭春梅, 宿慧, 王沧海, 王静, 丁鹏鹏, 刘红. 白光内镜下结直肠肿瘤性质预测模型的构建与验证[J]. 中华临床医师杂志(电子版), 2023, 17(06): 655-661.
[13] 王延召, 牛鹏飞, 丁长民, 高庆坤, 高兆亚, 安柯, 翟志超, 曾庆敏, 黄文生, 雷福明, 顾晋. 结直肠癌致腹壁巨大缺损的一期修补经验（附13例报告）[J]. 中华临床医师杂志(电子版), 2023, 17(05): 557-561.
[14] 任鹏涛, 郝英豪, 阮红训, 秦晓宁, 张苑, 李猛. Lnczc3h7a靶向CTHRC6对肠癌细胞的增殖和迁移的影响[J]. 中华临床医师杂志(电子版), 2023, 17(03): 320-325.
[15] 邓文珺, 李长政. 结肠镜检查前肠道清洁剂使用的研究进展[J]. 中华胃肠内镜电子杂志, 2023, 10(03): 192-194.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号